All Press Releases for November 27, 2024

Jason Wyatt Holder Celebrated for Dedication to the Biopharmaceutical Industry

Jason Wyatt Holder channels years of expertise into his work with Endolytix



Dr. Holder has featured his work in the Journal of Molecular Biology, Cell Biology, PLoS Genetics, Microbiology Spectrum, and others.

    SWAMPSCOTT, MA, November 27, 2024 /24-7PressRelease/ -- Jason Wyatt Holder has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

A seasoned scientist, engineer, and leader with years of expertise in biology and management, Dr. Holder excels as the co-founder and Chief Scientific Officer of Endolytix, which is driven to develop a novel therapeutic approach to address antibiotic resistance (AMR) in nontuberculous mycobacterial infections such as the MAC complex and Mycobacterium tuberculosis. In this capacity, he leads research and development efforts regarding antibiotic-resistant infections. In addition to handling most executive functions, Dr. Holder plays a vital role in raising capital for research and has filed for numerous patents for recombinant phage and methods of engineering recombinant phage, bacterial detection methods, and antibacterial therapeutics.

Before founding Endolytix, Dr. Holder honed his expertise as a principal member of Draper's technical staff. Between 2015 and 2019, he developed sensors for chemicals and bacteria and established the IDAST technology, which engineers luminescent bacteriophages for pathogenic bacteria detection, identification, and antibiotic susceptibility profiling. During the early stages of his career, he gained valuable expertise with Draper as a group leader and synthetic molecular engineer. He worked for entities such as The Broad Institute, Sample6 Technologies, the Johns Hopkins School of Medicine's Department of Cell Biology and did his PhD thesis work in the department of Molecular Biology and Genetics, at the Johns Hopkins School of Medicine.

Due to his vast knowledge, Dr. Holder has authored multiple articles on the genomic analysis of human fungal pathogens, comparative and functional genomics of Rhodococcus opacus for Biofuels production, Mitochondrial Biogenesis, Targeted transposition, Point of Care detection of pathogenic bacteria, and development of encapsulated enzymes for target destruction of mycobacteria. Along with other industry scholars, Dr. Holder has featured his work in the Journal of Molecular Biology, Cell Biology, PLoS Genetics, Microbiology Spectrum, and others.

An expert in his field, Dr. Holder earned a Bachelor of Science in Microbiology from Indiana University Bloomington in 1995. Subsequently, he expanded his professional knowledge by completing a PhD in Biochemistry, Cell, and Molecular Biology (BCMB program) from Johns Hopkins University and a postdoctoral fellowship in functional genomics and metabolic engineering through MIT and in collaboration with the Broad Institute. Given his educational and professional excellence, he earned a seed grant through the MIT Energy Initiative and the Cambridge MIT Partnership Program Exchange Grant. While his career has been filled with highlights, Dr. Holder takes the most pride in establishing Endolytix Technology Inc, which is a culmination of his knowledge and experiences. Since the switch he made from basic to applied biology, Dr. Holder has been awarded numerous patents in the field of biotechnology, with more going through the process in support of Endolytix Drug development program.

Though hard work and dedication have brought him far in his career, Dr. Holder credits his success to his mentors' guidance and desire to seek insight from every individual with whom he has worked. He intends to introduce new drugs for tuberculosis and nontuberculous bacterial infections to the market in attempt to provide a much needed alternative for patients with few to no good options.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #

Contact Information

-- --
Marquis Who's Who Ventures LLC
Uniondale, NY
USA
Voice: 844-394-6946
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: